Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Novo Nordisk A/S
  6. News
  7. Summary
    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novo Nordisk A/S : Share repurchase programme (Form 6-K)

08/04/2021 | 06:46am EDT

Novo Nordisk A/S - Share repurchase programme

Bagsværd, Denmark, 4 August 2021 - On 7 May 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the 'Safe Harbour Rules'). This programme is part of the overall share repurchase programme of up to DKK 18 billion to be executed during a 12-month period beginning 3 February 2021.

Under the programme initiated 7 May 2021, Novo Nordisk has repurchased B shares for an amount up to DKK 3.3 billion in the period from 10 May 2021 to 3 August 2021. The programme is now concluded.

Since the announcement as of 26 July 2021, the following transactions have been made:

Number of

B shares

Average

purchase price

Transaction

value, DKK

Accumulated, last announcement 5,656,169 2,903,108,782
26 July 2021 100,000 565.65 56,565,386
27 July 2021 100,000 562.97 56,297,265
28 July 2021 100,000 569.30 56,929,904
29 July 2021 100,000 573.34 57,333,894
30 July 2021 100,000 576.54 57,653,760
2 August 2021 100,000 577.19 57,719,398
3 August 2021 93,468 581.92 54,391,339
Accumulated under the programme 6,349,637 3,299,999,727

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

Page 2 of 2

With the transactions stated above, Novo Nordisk owns a total of 17,552,912 B shares of DKK 0.20 as treasury shares, corresponding to 0.8% of the share capital. The total amount of A and B shares in the company is 2,310,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 18 billion during a 12- month period beginning 3 February 2021. As of 3 August 2021, Novo Nordisk has since 3 February 2021 repurchased a total of 18,714,414 B shares at an average share price of DKK 474.84 per B share equal to a transaction value of DKK 8,886,358,976.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.

Further information

Media:
Mette Kruse Danielsen +45 3079 3883 mkd@novonordisk.com
Michael Bachner (US) +1 609 664 7308 mzyb@novonordisk.com
Investors:
Daniel Muusmann Bohsen +45 3075 2175 dabo@novonordisk.com
Ann Søndermølle Rendbæk +45 3075 2253 arnd@novonordisk.com
David Heiberg Landsted +45 3077 6915 dhel@novonordisk.com
Mark Joseph Root (US) +1 848 213 3219 mjhr@novonordisk.com

Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

Internet:
www.novonordisk.com
CVR no:

24 25 67 90

Company announcement No 47 / 2021

Disclaimer

Novo Nordisk A/S published this content on 04 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 August 2021 10:45:23 UTC.


ę Publicnow 2021
All news about NOVO NORDISK A/S
02:09aNOVO NORDISK A/S : Matheson Advises Novo Nordisk A/S On The Purchase Of Neotope Neuroscien..
AQ
09/24Health Care Stocks Under Pressure Near Friday Close
MT
09/24NOVO NORDISK A/S : to Settle US Securities Class Action Lawsuit for $100 Million
MT
09/21European ADRs Move Higher in Tuesday Trading
MT
09/20NOVO NORDISK A/S : Share repurchase programme (Form 6-K)
PU
09/20NOVO NORDISK A/S : – Share repurchase programme
AQ
09/16VC DAILY : Venture Capitalists Push Back Against -2-
DJ
09/14ANALYST RECOMMENDATIONS : Apple, Bank of America, Cisco, DT Midstream, Halliburton...
09/14NOVO NORDISK : Jefferies reiterates its Sell rating
MD
09/13NOVO NORDISK A/S : Share repurchase programme (Form 6-K)
PU
More news
Analyst Recommendations on NOVO NORDISK A/S
More recommendations
Financials
Sales 2021 137 B 21 633 M 21 633 M
Net income 2021 46 316 M 7 301 M 7 301 M
Net cash 2021 6 163 M 971 M 971 M
P/E ratio 2021 31,9x
Yield 2021 1,55%
Capitalization 1 470 B 231 B 232 B
EV / Sales 2021 10,7x
EV / Sales 2022 9,68x
Nbr of Employees 45 971
Free-Float 69,8%
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 27
Last Close Price 641,90 DKK
Average target price 608,04 DKK
Spread / Average Target -5,27%
EPS Revisions
Managers and Directors
Lars Fruergaard J°rgensen President & Chief Executive Officer
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Helge Lund Chairman
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Henrik Ehlers Wulff Executive VP & Head-Information Technology
Sector and Competitors
1st jan.Capi. (M$)
NOVO NORDISK A/S50.45%231 485
JOHNSON & JOHNSON4.44%432 675
ROCHE HOLDING AG10.16%321 605
PFIZER, INC.20.05%246 358
ELI LILLY AND COMPANY37.22%210 037
ABBVIE INC.-0.07%189 211